Evidence map›Paper›PMID 40196437›Full record

ArticleBMJ public health2025

The issue with incidence: a scoping review of reported medication-related osteonecrosis of the jaws (MRONJ) incidence around the globe.

Ailish Suzanne Emuss Clark, Anne-Marie Glenny

Abstract read
In one paragraph

Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Post-COVID-19 Jaw Osteonecrosis: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ailish Suzanne Emuss ClarkThe University of Manchester Faculty of Biology Medicine and Health, Manchester, UK.ORCID 0000-0002-0670-7280
Anne-Marie GlennyThe University of Manchester Faculty of Biology Medicine and Health, Manchester, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Medication-related osteonecrosis of the jaws (MRONJ) can be a debilitating condition which is challenging to manage. While vast literature exists surrounding MRONJ, many studies have small participant numbers and are heterogeneous in design, leaving unanswered questions and making evidence-based practice challenging. Objective: Provide an overview of recent MRONJ incidence data, over a 5-year period, identify potential issues in reporting MRONJ cases and propose changes for future reporting. Eligibility criteria: Studies with original data regarding MRONJ incidence published from 2015 to 2020. Sources of evidence: A search was conducted on MEDLINE Ovid, the National Library of Medicine's bibliographic database, using a combination of medical subject headings (MeSH) and free text terms and run on 29 April 2021. Charting method: Each title was hand-screened, and the abstract/article in full was reviewed to establish suitability for inclusion by two authors. Data extraction by two reviewers included author, year of publication, study design, population-cancer/osteoporosis/both/other, description of population, sampling method, exclusion criteria, single centre Y/N, reported rate of MRONJ cases/number of participants, details of diagnosis and diagnostic criteria, duration of follow-up and location of study. Results: The initial search returned 1186 titles, detailed screening and inclusion of additions resulted in 92 articles for data extraction. Mean incidence of MRONJ across all studies was 4.34% (median 2.42%, range 0% to 31.80%). The mean incidence based on patient group was oncology 6.22% (32 954 participants), osteoporosis 0.58% (498 443 participants), oncology and osteoporosis 7.21% (54 7651 participants) and other, including autoimmune, inflammatory and other bone conditions, 2.55% (4487 participants). Further analysis showed incidence influenced by study size (>500 participants), diagnostic criteria used, location of study and other factors. Conclusion: Heterogeneity in studies reporting MRONJ incidence impacts results and conclusions. Standardised, contemporaneous reporting of MRONJ cases would eliminate this variation and provide valuable insight into the epidemiology, natural history and outcomes of these patients, supporting evidence-based management and service provision of patients affected.

Indexed as

Adverse Drug Reaction Reporting SystemsData CollectionDrug MonitoringEpidemiology

Identifiers

PMID40196437
PMCPMC11973752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.